4.2.3 Targeted therapies and immunotherapy

Several novel agents are approved for relapsed lymphoma:

  • brentuximab vedotin, which targets CD30 expressing cells, for treating recurrent Hodgkin lymphoma
  • pembrolizumab for treating recurrent Hodgkin lymphoma and primary mediastinal B-cell lymphoma
  • CAR T-cell therapy, Kymriah, for patients with recurrent DLBCL and primary mediastinal large B-cell lymphoma after autologous transplantation or two lines of systemic therapy.